Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

The Evanston college claims Moderna could not have developed the vaccine as quickly as it did in 2020 without its own ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Moderna (NasdaqGS:MRNA) with a Market Perform ...

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $54.82 which represents a decrease of $-2.64 or -4.59% from the prior close of $57.46. The stock opened at $57.08 and touched a ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are ...

The vaccine that’s helped protect millions of people worldwide from the COVID-19 virus and its variants would not have been ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

COVID has changed so much from the first few years of the pandemic, when people got those first vaccines in 2021,” said Dr. Doug Pogue, president of BJC Medical Group.

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.